Introduction
============

Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLEHS) is typically a serious epilepsy syndrome and the most common drug-resistant epilepsy ([@awt233-B5]). It is associated with burdensome co-morbidities, such as memory and psychiatric disorders. MTLEHS is the epilepsy most considered for therapeutic neurosurgery. Although surgery is a proven therapy, only ∼50% of patients have sustained postoperative seizure freedom ([@awt233-B9]), and surgery can have important adverse consequences. Better treatment options, or even prevention, of MTLEHS are therefore needed, but rational therapy for MTLEHS remains elusive because its causes are obscure ([@awt233-B25]).

MTLEHS is associated with a history of febrile seizures in childhood ([@awt233-B29]; [@awt233-B25]). About 3% of children have febrile seizures; why only some go on to develop epilepsy, including MTLEHS, is unknown. There are a number of rare, genetically-determined, epilepsy syndromes in which febrile seizures are a prominent feature, such as Dravet syndrome and 'genetic epilepsy with febrile seizures plus' (GEFS+) ([@awt233-B27]). MTLEHS has rarely been described in families with GEFS+ ([@awt233-B2]) or familial febrile seizures ([@awt233-B20]) associated with *SCN1A* mutations. In familial mesial temporal lobe epilepsy, some family members may have hippocampal sclerosis ([@awt233-B15]). A cluster of families with mesial temporal lobe epilepsy with hippocampal changes has been described in Brazil ([@awt233-B3]). Together, this evidence implies genetic susceptibility to MTLEHS, although its heritability is unknown.

We hypothesized that MTLEHS, or MTLEHS with febrile seizures, as common epilepsy syndromes, might be associated with common genetic variation, and tested this 'common disease-common variant' hypothesis in a genetic association study.

Materials and methods
=====================

All aspects of the study were approved by the relevant institutional review board. All participants gave written informed consent.

Subjects
--------

Patients were recruited during clinical appointments. MTLEHS was defined as in [@awt233-B35]. The diagnosis was made and/or reviewed by a consultant epileptologist who was part of this study, with access to history and investigation results. Patients with bilateral hippocampal sclerosis or dual pathology were excluded. One thousand and eighteen patients were included in the discovery stage and 959 patients in the replication. The number of patients by country is shown in [Table 1](#awt233-T1){ref-type="table"}, with further details in [Supplementary Table 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1). A history of presence or absence of febrile seizures was accepted only if contemporary medical records or a parental account was available; otherwise it was considered unknown, and not eligible for analysis. Population-based controls (*n* = 7552) were included in the discovery stage, and 3591 in the replication ([Table 1](#awt233-T1){ref-type="table"} and [Supplementary Table 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)). Table 1Number of individuals included in the study, after removal of population outliers and individuals of non-European ancestryPopulationPatients with MTLEHSIndividuals with a definite history of febrile seizuresIndividuals with a definite history of no febrile seizuresControls**Discovery**Austria15745104332Belgium672320285USA712345605Finland11618     0[\*](#awt233-TF1){ref-type="table-fn"}746Ireland1485490209UK2771171015116Switzerland18261     0[\*](#awt233-TF1){ref-type="table-fn"}259**Total discovery10183413607552Replication**Austria571839254Germany273112161346Portugal1025448190UK804228857Netherlands16474     0[\*](#awt233-TF1){ref-type="table-fn"}601Italy441826249Australia1628379794USA771562300**Total replication9594164433591Febrile seizures study**AustriaNA158NA 585[\*\*](#awt233-TF2){ref-type="table-fn"}GermanyNA212NA 346[\*\*\*](#awt233-TF3){ref-type="table-fn"}UK (ALSPAC)NA172NA6456**Total febrile seizures**NA**542**NA**7387**[^3][^4][^5][^6]

We also studied 542 individuals who had had febrile seizures but by the last follow-up had not had unprovoked seizures. These came from three groups: a German group; an Austrian group and the ALSPAC (Avon Longitudinal Study of Parents and Children) cohort, the latter followed to age 13 years ([Supplementary material](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)); MTLEHS after febrile seizures almost always develops by the age of 15 ([@awt233-B24]). These cases were compared with 7387 control subjects from three relevant populations ([Table 1](#awt233-T1){ref-type="table"}). For the German and Austrian samples, the same controls as in the MTLEHS study were used.

To minimize population stratification, only individuals of white European ancestry were included. In the discovery stage, a combination of self-identified ancestry and EIGENSTRAT principal component methods was used to determine European ancestry. In the replication and febrile seizures analyses, only self-reported white individuals of European ancestry were included. More detailed ancestry data were available from all sources except Austria, allowing exclusion of individuals self-reported as coming from countries other than those where they were recruited.

Genotyping and quality control
------------------------------

In the discovery stage, all but the Austrian samples and Belgian controls comprised a subset of a previously described data set ([@awt233-B13]), genotyped on Illumina genome-wide genotyping chips, mostly on Illumina Human610-Quadv1/Human1-2M-DuoCustom. One hundred and fifty-seven Austrian patients and 332 controls were genotyped on Illumina HumanCNV370duo, and 285 Belgian controls were genotyped on Illumina HumanHap300 genotyping chips. Gender and relatedness checks were performed on all samples. The cluster plots of the top-associated single nucleotide polymorphisms were inspected manually. Details are given in [@awt233-B13] and in the online [Supplementary material](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1). For replication analysis, several methods were used for genotyping.

Statistical analysis
--------------------

In the discovery stage, genome-wide association analysis was performed using PLINK. Only single nucleotide polymorphisms present on both Illumina Human610-Quadv1 and Human1-2M-DuoCustom were analysed. In the discovery stage, we performed logistic regression using an additive model, including all significant EIGENSTRAT axes (assessed using the Tracy-Widom statistic with *P* \< 0.05) as covariates. Only single nucleotide polymorphisms with minor allele frequency of ≥ 1% were analysed. Since the replication samples did not have genome-wide data available to calculate EIGENSTRAT axes, we performed stratified analysis using the Cochran-Mantel-Haenszel test for 2 × 2 × 8 stratified case-control subsamples deriving from eight different recruitment countries and self-identified ancestry, using R. The Woolf test was used to assess effect heterogeneity. Meta-analysis of discovery and replication studies was performed using the inverse variance-weighted fixed-effects model as implemented in the GWAMA software ([@awt233-B19]). We considered an association to be genome-wide significant at *P* \< 5 × 10^−8^.

To fine map the association signal in the discovery stage, we imputed single nucleotide polymorphisms in the 10 Mb region surrounding rs7587026. Imputation was performed using MINIMAC ([@awt233-B11]), and 1000 Genomes Project data ([@awt233-B1]) as the reference data set. Subsequent association analysis was performed using MACH2DAT ([@awt233-B17]) using significant EIGENSTRAT axes as covariates.

Power calculations were performed using Genetic Power Calculator ([@awt233-B30]).

Expression analysis
-------------------

We tested association between genotypes of the two top single nucleotide polymorphisms rs7587026 and rs11692675 and *SCN1A* exons and gene expression in the middle temporal cortex (Brodmann areas 20 and 21) from 78 patients with MTLEHS who had undergone surgical resection, compared with 78 neurologically normal individuals from the MRC Sudden Death Brain and Tissue Bank. We specifically chose not to study the hippocampus to avoid confounding due to tissue changes such as cell loss and gliosis. All samples were randomly hybridized to Affymetrix Human Exon 1.0 ST arrays. Differential expression of *SCN1A* transcripts incorporating the 'neonatal' or 'adult' exon 5 form (5N or 5A exon, respectively), and expression of non-coding exons 1a and 1b (GenBank accession numbers DQ993522 and DQ993523, respectively) ([@awt233-B21]) in the 5' region of *SCN1A*, were tested by quantitative RT-PCR as they are not covered by the array. Details are provided in the [Supplementary material](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1).

Further, we tested whether the associated single nucleotide polymorphisms have an effect on expression or splicing of any genes in the genome in post-mortem tissue of nine brain regions from 134 control individuals ([Supplementary material](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)).

Results
=======

Genome-wide association analyses
--------------------------------

We performed a two-stage study. For discovery, we first investigated genome-wide association between all MTLEHS and 531 164 single nucleotide polymorphisms in 1018 MTLEHS cases and 7552 controls from seven populations of European descent ([Table 1](#awt233-T1){ref-type="table"} and [Supplementary Table 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)). Using logistic regression analysis and correcting for population stratification, suggestive association emerged for three single nucleotide polymorphisms in a region of strong linkage disequilibrium on chromosome 2q24.3 encompassing *SCN1A* and other sodium channel genes ([Supplementary Fig. 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)). The most strongly associated single nucleotide polymorphism, rs11692675, is within intron 3 of the *SCN1A* full-length transcript variant (NM_001202435.1) {*P* = 5.26 × 10^−8^, odds ratio for G allele \[OR(G)\] 1.31, 95% confidence interval (CI) 1.19--1.44; [Table 2](#awt233-T2){ref-type="table"}}. Two other single nucleotide polymorphisms within *SCN1A* intron 1, had similarly low *P*-values: rs7587026 (r^2^= 0.806 with rs11692675 in CEU population based on 1000 Genomes data set), *P* = 1.19 × 10^−7^ \[OR(A) = 1.31, 95% CI: 1.19--1.45\]; and rs580041 (r^2^= 0.806 with rs11692675), *P* = 5.74 × 10^−7^ \[OR(A) = 1.29, 95% CI: 1.17--1.43\]. Table 2Genotype counts, allele frequencies and association results for rs7587026 and rs11692675 SNPs in the MTLEHS studySNP*n* patients*n* controlsMinor alleleGenotype count in patientsGenotype count in controlsMinor allele frequency in patientsMinor allele frequency in controls*P*-value[\*](#awt233-TF4){ref-type="table-fn"}Odds ratio (95% CI)**Discovery*MTLEHS versus controls***rs758702610177549A99/440/478536/2895/41180.3140.2631.19 × 10^--7^1.31 (1.19--1.45)rs1169267510187547G147/477/394794/3352/34010.3790.3275.26 × 10^--8^1.31 (1.19--1.44)***MTLEHS+FS versus controls***rs75870263417549A43/161/137536/2895/41180.3620.2632.64 × 10^--8^1.59 (1.35--1.87)rs116926753417547G61/163/117794/3352/34010.4180.3271.25 × 10^--6^1.49 (1.27--1.75)***MTLEHS−FS versus controls***rs75870263596544A30/143/186469/2528/25470.2830.2650.211.12 (0.94--1.33)rs116926753606542G48/167/145698/2951/28930.3650.3320.0391.19 (1.01--1.40)***MTLEHS+FS versus MTLEHS−FS***rs7587026341359A43/161/13730/143/1860.3620.2831.12 × 10^--3^1.48 (1.17--1.87)rs11692675341360G61/163/11748/167/1450.4180.3650.0301.28 (1.03--1.59)**Replication*MTLEHS versus controls***rs75870269333537A89/360/484247/1361/19290.2880.2620.0251.15 (1.02--1.29)rs116926758263568G108/364/354394/1615/15590.3510.3370.191.08 (0.96--1.21)***MTLEHS+FS versus controls***rs75870264063537A43/163/200247/1361/19290.3070.2625.88 × 10^--3^1.26 (1.07--1.48)rs116926753713568G56/156/159394/1615/15590.3610.3370.121.14 (0.97--1.34)***MTLEHS−FS versus controls***rs75870264362972A42/160/234216/1136/16200.2800.2640.201.11 (0.95--1.31)rs116926753572983G42/164/151336/1332/13150.3470.3360.351.08 (0.92--1.27)***MTLEHS+FS versus MTLEHS−FS***rs7587026338436A35/137/16642/160/2340.3060.2800.221.16 (0.93--1.44)rs11692675298357G46/125/12742/164/1510.3640.3470.501.09 (0.87--1.36)**Combined (meta-analysis)*MTLEHS versus controls***rs7587026195011 086A188/800/962783/4256/60470.3020.2633.78 × 10^--8^1.24 (1.15--1.34)rs11692675184411 115G255/841/7481188/4967/49600.3660.3304.87 × 10^--7^1.21 (1.12--1.30)***MTLEHS+FS versus controls***rs758702674711 086A86/324/337783/4256/60470.3320.2633.36 × 10^--9^1.42 (1.26--1.59)rs1169267571211 115G117/319/2761188/4967/49600.3880.3304.78 × 10^--6^1.30 (1.16--1.46)***MTLEHS−FS versus controls***rs75870267959516A72/303/420685/3664/51670.2810.2650.0671.12 (0.99--1.25)rs116926757179525G90/331/2961034/4283/42080.3560.3330.0331.13 (1.01--1.27)***MTLEHS+FS versus MTLEHS−FS***rs7587026679795A78/298/30372/303/4200.3340.2811.53 × 10^--3^1.30 (1.10--1.52)rs11692675639717G107/288/24490/331/2960.3930.3560.0391.18 (1.01--1.38)[^7]

*SCN1A* encodes brain-expressed voltage-gated sodium channel type I, alpha subunit. It bears the largest number of known epilepsy-related mutations, some associated with febrile seizures ([@awt233-B27]). The common *SCN1A* single nucleotide polymorphism rs3812718, affecting splicing ([@awt233-B10]), has also been associated with febrile seizures ([@awt233-B31]), though replication has failed ([@awt233-B28]). Retrospective studies show association between MTLE and febrile seizures ([@awt233-B29]; [@awt233-B25]). Whether febrile seizures cause MTLEHS ([@awt233-B14]) or whether pre-existing hippocampal abnormalities predispose to febrile seizures ([@awt233-B8]), which may then also be injurious, is unknown. Clinical differences between patients with and without a history of febrile seizures suggest MTLEHS is heterogeneous ([@awt233-B33]).

This evidence motivated our pre-analysis collection of febrile seizure data, and our previous study of febrile seizures ([@awt233-B28]). We performed analysis of patients in the discovery cohort with a known history of presence of childhood febrile seizures (MTLEHS + FS, *n* = 341) ([Table 2](#awt233-T2){ref-type="table"} and [Fig. 1](#awt233-F1){ref-type="fig"}). The strongest association was for rs7587026, *P* = 2.64 × 10^−8^ \[OR(A) = 1.59, 95% CI: 1.35--1.87\] and rs580041, *P* = 8.91 × 10^−7^ \[OR(A) = 1.56, 95% CI: 1.33--1.84\], whereas the signal for rs11692675 was slightly weaker, *P* = 1.25 × 10^−6^ \[OR(G) = 1.49, 95% CI: 1.27--1.75\]. No association was seen in patients with MTLEHS without febrile seizures (MTLEHS−FS), despite similar sample size. Figure 1The results of genome-wide association analysis in MTLEHS+FS in discovery stage. (**A**) Manhattan plot, −log~10~ (*P*-values) of the logistic regression test are plotted against single nucleotide polymorphism positions on each chromosome. (**B**) Quantile-quantile plot, the grey shaded area represents the 95% confidence interval of expected −log~10~ (*P*-values). Black dots represent the observed *P*-values; λ = 1.022. (**C**) Regional association results for the chromosome 2q24.3 locus. The left *y*-axis represents −log~10~ (*P*-values) for association with MTLEHS, the right *y*-axis represents the recombination rate, and the *x*-axis represents base-pair positions along the chromosome (human genome Build 37). The top single nucleotide polymorphism, rs7587026, is shown in purple, the rest of the single nucleotide polymorphisms are coloured according to their linkage disequilibrium r^2^ value with rs7587026.

To refine the association signal, we performed regional imputation in the discovery data set of a 10 Mb region surrounding rs7587026 using the 1000 Genomes reference panel. Two single nucleotide polymorphisms had slightly lower *P*-values in the MTLEHS+FS analysis than the original single nucleotide polymorphisms \[rs16851603 (*P* = 2.23 × 10^−8^) and rs3919196 (*P* = 2.26 × 10^−8^)\], but neither were significantly stronger than the original associations, and these signals reflected regional linkage disequilibrium structure ([Supplementary Fig. 2](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)). No known functional variants in *SCN1A*, nor in other genes in the region, were in high linkage disequilibrium with rs7587026. The association signal is localized within one linkage disequilibrium block that also spans the promoter and 5' UTR region of *SCN1A* ([Supplementary Fig. 2](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)).

Replication and combined analyses
---------------------------------

We selected the two top single nucleotide polymorphisms, rs7587026 and rs11692675, for replication in an independent sample of 959 patients with MTLEHS, of whom 416 had MTLEHS+FS, and 3591 population-matched controls of European descent from eight populations ([Table 1](#awt233-T1){ref-type="table"} and [Supplementary Table 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)). We did not study rs580041 because of its perfect linkage disequilibrium with rs7587026 in white Europeans (r^2^= 1). We detected an association between rs7587026 and MTLEHS + FS, *P* = 5.88 × 10^−3^ \[OR(A) = 1.26, 95% CI: 1.07--1.48; [Table 2](#awt233-T2){ref-type="table"}\]; this value remains significant at a revised alpha threshold of 6.3 × 10^−3^ after Bonferroni correction for multiple comparisons in the replication cohort. No association was detected for MTLEHS−FS.

Meta-analysis of the discovery and replication samples confirmed the association of the 2q24.3 locus with MTLEHS+FS at genome-wide significant level for rs7587026 \[*P~meta~* = 3.36 × 10^−9^, OR(A) = 1.42, 95% CI: 1.26--1.59\]; the signal for rs11692675 did not reach genome-wide significance \[*P~meta~* = 4.78 × 10^−6^, OR(G) = 1.30, 95% CI: 1.16--1.46\]. No significant heterogeneity in effect sizes was detected among different populations ([Fig. 2](#awt233-F2){ref-type="fig"}, Woolf's test for heterogeneity *P* = 0.45, see [Supplementary Tables 7--10](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1) for allele frequencies in all populations). Figure 2Forest plot for association of rs7587026 with MTLEHS+FS. The confidence interval for each study population is given by a horizontal line, and the point estimate is given by a square whose area is inversely proportional to the standard error of the estimate. The combined odds ratio is drawn as a diamond with horizontal limits at the confidence limits and width inversely proportional to its standard error. The study populations are ordered in descending order by the number of MTLEHS+FS cases.

Febrile seizure analysis
------------------------

To explore whether the observed association with rs7587026 is specific for MTLEHS+FS, or is specific for febrile seizures in general, we examined a total of 7387 controls and three data sets of patients (totalling 542) who had had febrile seizures but had not developed epilepsy by the time of the latest follow-up. It has been shown that almost all children who go on to develop any type of epilepsy after febrile seizures have done so by the age of 15 years ([@awt233-B24]). Therefore, to address the specificity of the association for MTLEHS+FS rather than febrile seizures alone, the ideal febrile seizures cohort would have been followed to age 15 at least. Of the three data sets available to us, only one met this criterion closely. The ALSPAC prospective cohort, which has the most comprehensive phenotypic data of the three data sets, followed children to age 13: there was no association of rs7587026 with febrile seizures in 171 individuals who did not go on to develop epilepsy ([Table 3](#awt233-T3){ref-type="table"}) in comparison with 6443 controls from the same cohort. The two other cohorts of children with febrile seizures, from Austria \[samples partially overlapping with those reported in [@awt233-B31]\] and Germany, were ascertained at a young age (to six years of age only) and had no follow-up to establish whether the children had febrile seizures only, or febrile seizures in the context of subsequent epilepsy including MTLEHS, and are therefore not best suited to address the question, but were examined as few cohorts overall are available. Bearing this key caveat in mind, in these two data sets there was an observed association of febrile seizures with rs7587026 ([Table 3](#awt233-T3){ref-type="table"}). The previously reported association in the Austrian population with an *SCN1A* functional splice-site single nucleotide polymorphism, rs3812718, was also seen in our Austrian sample \[which is not unexpected as there is partial overlap of cases with those in the original report ([@awt233-B31])\] and was present in the German sample. The observed association of rs7587026 with febrile seizures disappeared in both Austrian and German data sets when analysis was conditioned on rs3812718 (*P* \> 0.19; [Table 3](#awt233-T3){ref-type="table"}). Moreover, although the association of febrile seizures with rs3812718 may be thought to be of interest for pure febrile seizures alone, we note there is no association of rs3812718 with febrile seizures in the best characterized cohort, from ALSPAC ([Table 3](#awt233-T3){ref-type="table"}), nor in a published sample ([@awt233-B28]). Table 3Genotype counts, allele frequencies and association results for rs7587026, rs3812718 and rs922224 in febrile seizures stagePopulation*n* patients*n* controlsMinor alleleGenotype count in patientsGenotype count in controlsMinor allele frequency in patientsMinor allele frequency in controls*P*-value in single SNP association (allelic χ^2^ test)*P*-value in conditional analysis[\*\*](#awt233-TF6){ref-type="table-fn"}**rs7587026**Austria158584A19/58/8131/216/3370.3040.2380.0170.19Germany194337A15/92/8720/116/2010.3140.2310.0030.43UK (ALSPAC)1716443A23/59/89498/2550/33950.3070.2750.1940.33[\*](#awt233-TF5){ref-type="table-fn"}**rs3812718**Austria133209G16/65/5252/100/570.3650.4880.00150.030Germany212344G32/98/8288/166/900.3820.4970.000180.0012**rs922224 (proxy for rs3812718)**UK (ALSPAC)1726456G34/81/571371/3144/19410.4330.4560.400.83[\*](#awt233-TF5){ref-type="table-fn"}[^8][^9]

Thus, although other single nucleotide polymorphisms in or near *SCN1A* may predispose to pure febrile seizures, the signal we observed in MTLEHS+FS is very unlikely to be due to the history of febrile seizures alone. Moreover, no significant association was detected in a group of patients with other partial epilepsies with a history of febrile seizures \[data set from [@awt233-B13]; rs7587026, *P* = 0.24, OR(A) = 1.15, 95% CI: 0.91--1.45\]. The sample for this analysis was smaller (177 patients; 7552 controls), but had 81% power to detect association of OR ≥ 1.42 (as seen in MTLEHS+FS group combined analysis) under 0.05 significance level. Collectively, we found no evidence that the MTLEHS+FS association was due to febrile seizures, or that it holds for all partial epilepsies with febrile seizures.

*SCN1A* expression in the human brain
-------------------------------------

The observed association could act by modulating *SCN1A* gene expression. The associated region harbours several alternative untranslated *SCN1A* exons ([@awt233-B21]; [@awt233-B23]). We did not detect association between rs7587026 and any protein-coding exon except one (see below) or total *SCN1A* expression, or with expression of untranslated 5' exons 1a and 1b ([@awt233-B21]) (data not shown) in 78 patients and 78 control subjects.

The presence or absence of transcripts incorporating the 'neonatal' *SCN1A* exon 5 ('5N') was significantly different according to genotype of the two top single nucleotide polymorphisms (rs11692675 and rs7587026, *P*-values 1.08 × 10^−9^ and 1.17 × 10^−6^, respectively; [Supplementary material](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)). For rs11692675 and rs7587026, respectively, none and 1% of the individuals with the GG and AA genotype showed *SCN1A* transcripts in the neonatal form, compared with 83% and 81% with the genotype AA or CC. This alternative splicing event is influenced by rs3812718 ([@awt233-B10]). The association of alternative splicing with rs922224 (r^2^= 1 with rs3812718) was stronger, *P* = 2.33 × 10^−31^. The level of expression of *SCN1A* exon 5N was also significantly different according to genotype (*P* = 1.62 × 10^−11^ for rs11692675, 2.70 × 10^−6^ for rs7587026, 7.40 × 10^−34^ for rs922224). In conditional analyses including all three single nucleotide polymorphisms, only rs922224 remained significant (*P* = 1.08 × 10^−25^). Finally, expression quantitative trait loci analyses for subsets of patients according to a known history of presence (*n* = 46) or absence (*n* = 27) of febrile seizures in childhood for rs11692675 or rs7587026 showed significant differences in the level of expression of 5N exon according to genotype in both MTLEHS+FS and MTLEHS−FS. Including both rs11692675 or rs11692675 and rs922224 in the regression models, only rs922224 remained significant in both MTLEHS+FS and MTLEHS−FS groups ([Supplementary material](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)).

We cannot exclude the possibility that rs7587026 (or another single nucleotide polymorphism in the high linkage disequilibrium region) may act as an additional splicing controller to rs3812718, but our data are consistent with rs7587026 having no solo effect on 5N splicing. We also did not detect any correlation using a significance level of *P* \< 5 × 10^−5^ between rs7587026 and expression/splicing of any other genes across the genome ([Supplementary material](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt233/-/DC1)).

Discussion
==========

We show that common variation in and near *SCN1A* may increase susceptibility to MTLEHS+FS. Our previously published larger genome-wide association study for a broader range of focal epilepsies did not identify any single-single nucleotide polymorphism association ([@awt233-B13]), but the findings here demonstrate that associated variants may exist for more narrowly-defined syndromes. Because the biology of most of the epilepsies is poorly understood, there are few *a priori* data upon which to base selection of the range of phenotypes to include in studies of possible genetic causation. Our findings suggest that focussing on clinically recognized syndromes or constellations ([@awt233-B5]) may prove fruitful by reducing heterogeneity before genomic analyses.

Our association seems to be specific for MTLEHS+FS, with no association for MTLEHS−FS, febrile seizures alone or non-MTLEHS partial epilepsies with febrile seizures. Our findings suggest that there is genetic susceptibility to MTLEHS, and that it, or hippocampal sclerosis, may not necessarily be only acquired. The results support the concept of heterogeneity in MTLEHS, beyond that already documented clinico-pathologically ([@awt233-B32]; [@awt233-B33]; [@awt233-B6]). However, further work will be needed to confirm the specificity of our findings, as we did not formally establish a significant difference in odds ratios between MTLEHS+FS and MTLEHS−FS. It would also be interesting to explore, in a suitably-powered study, whether there is any association with MTLE without hippocampal sclerosis.

The notably weaker association in the replication stage could be due to several factors, the most important of which is the 'winner's curse' ([@awt233-B12]); there may be a large number of weak but real associations in the data, some of which achieve genome-wide significance in a particular study through random stochastic chance, but will not do so in another study. The association in our discovery cohort was replicated in the second independent sample, but it is nevertheless important that other studies are undertaken to further replicate our findings. Other limitations of our study are the lack of genome-wide data in the replication sample, preventing direct population stratification assessment, though self-identification closely corresponds to genetically-determined ancestry ([@awt233-B16]; [@awt233-B34]), a phenomenon we confirmed in the discovery stage, and the small size of some of the replication groups, reducing replication power, and magnifying effects of undetected population admixture.

As for many genome-wide association studies, we could not narrow the association to a single gene or functional variant. There are other genes designated '*SCNxA*' in the vicinity: *SCN3A*, *SCN2A*, *SCN9A* and *SCN7A* (this last does not show any sodium channel activity in exogenous expression systems) ([@awt233-B22]). Among these genes, *SCN2A* has the most published evidence to support its role in the epilepsies. We cannot exclude the possibility that the association is driven by deleterious variants in these or other nearby genes. *SCN1A*, however, emerges as the most plausible candidate, due both to its proximity to the associated region and its role in other epilepsies with febrile seizures. Notably, our association is with a syndrome involving hippocampal damage, whereas typically no hippocampal damage is observed in patients with Dravet syndrome caused by deleterious changes affecting *SCN1A* ([@awt233-B7]), suggesting that *SCN1A* might influence epileptogenesis through various mechanisms.

The location of the associated variants within *SCN1A* and overlapping its promoter regions ([@awt233-B18]), was suggestive of possible roles in *SCN1A* expression modulation. In fact, we did not detect a definitive effect on expression of *SCN1A* or its exons in temporal neocortex. However, this analysis may have been confounded by many factors: effects may be brain-region or cell-population specific, as in *SCN1A*-related Dravet syndrome, where consequences are only found in interneurons ([@awt233-B26]); our whole-tissue expression analysis would not detect such subtle signals. Moreover, noting the febrile seizures association, the effects may be temporally or spatially restricted, acting only in childhood or/and in the stress of febrile seizures ([@awt233-B14]). Further studies will be needed to explore possible functional effects.

The detected association could act in different ways, predisposing to MTLEHS+FS as a distinct syndrome, or to the specific development of MTLEHS in the context of remote febrile seizures. If the association does indeed relate to *SCN1A* and function of the encoded protein, new lines of investigation may prove possible in the context of the existing deep knowledge of *SCN1A*, experimental models of MTLE and *in vitro* study of mechanisms of hippocampal dysfunction in epilepsy, as well as intriguing reports of the role of *SCN1A* in many epilepsies, such as the suggestion that mutations in *SCN1A* in Dravet Syndrome may protect against hippocampal sclerosis ([@awt233-B4]; [@awt233-B7]). Stratifying by febrile seizures type could also prove illuminating, as prolonged, lateralized or repeated febrile seizures within a short interval may have different effects to 'uncomplicated' febrile seizures. Our retrospective febrile seizures data were insufficiently resolved to permit such analysis. This is an important avenue for further investigation, because no predictors exist for the development of epilepsy in the 3% of all the children who have febrile seizures, and because established MTLEHS can have devastating consequences. Eventual reliable prediction of significant risk of MTLEHS after febrile seizures could lead to novel preventative measures in at-risk individuals: here, we note that *SCN1A* encodes an important anti-epileptic drug target and that it is possible to pharmacologically prevent the development of epilepsy after febrile seizures in an animal model ([@awt233-B14]). Our findings suggest that further work on *SCN1A* variation may contribute to understanding the risk of developing MTLEHS after febrile seizures.
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MTLEHS

:   mesial temporal lobe epilepsy with hippocampal sclerosis

MTLEHS+FS

:   MTLEHS with febrile seizures

MTLEHS--FS

:   MTLEHS without febrile seizures

[^1]: \*These authors contributed equally to this work.

[^2]: ^†^The list of members of the UK Brain Expression Consortium is available at <http://ukbec.wordpress.com>.

[^3]: NA = not applicable.

[^4]: \*Data were not collected according to the criteria used in the study.

[^5]: \*\*Combined discovery and replication Austrian controls.

[^6]: \*\*\*Same as replication German controls.

[^7]: \*In discovery stage, *P*-value is logistic regression *P*-value for additive genetic model; in replication stage, Cochran-Mantel-Haenszel test *P*-value.

[^8]: \*Conditional analysis performed despite a non-significant single SNP association.

[^9]: \*\*In conditional analyses, rs7587026 was conditioned for rs3812718 (or its proxy, rs922224, for the ALSPAC cohort), while rs3812718 and rs922224 were conditioned for rs7587026.
